Table 1 Patient characteristics.
Characteristic | DL1 n = 3 | DL2 n = 3 | DL3 n = 4 | DL4 n = 6 | DL5 n = 4 |
|---|---|---|---|---|---|
Age, median (range) (years) | 62 (51–69) | 60 (51–63) | 62.5 (52–69) | 56.5 (54–60) | 61 (57–67) |
ECOG PS, n (%) | |||||
0 | 2 (66.7) | 2 (66.7) | 1 (25) | 5 (83.3) | 2 (50) |
1 | 1 (33.3) | 1 (33.3) | 3 (75) | 1 (16.7) | 2 (50) |
BSA, median (range) (m2) | 1.59 (1.57–1.65) | 1.9 (1.63–2.03) | 1.78 (1.69–1.92) | 1.78 (1.63–1.82) | 1.59 (1.54–1.63) |
Primary tumor type, n (%) | |||||
Ovarian cancer | 3 (100) | 3 (100) | 2 (50) | 5 (83.3) | 2 (50) |
High histological grade | 3 (100) | 2 (66.7) | 2 (100) | 5 (100) | 1 (25) |
Endometrium cancer | – | – | 2 | – | 1 (25) |
Uterine leiomyosarcoma | – | – | – | 1 (17.7) | |
Time from diagnosis to the inclusion, median (range) (months) | 80.3 (11–127) | 38.1 (26–61) | 71.5 (58–99) | 56.1 (39–61) | 33.9 (16–72) |
Lines of previous systemic therapy, median (range) | 5 (1–6) | 4 (4–6) | 4 (2–6) | 5 (3–6) | 5 (3–7) |
Previous radiotherapy, n (%) | – | – | 2 (50) | 1 (25) | |
Metastasis at baseline, n (%) | |||||
Lung | – | – | 1 (25) | 1 (16.7) | 2 (50) |
Liver | 1 (33.3) | 1 (33.3) | 1 (25) | 1 (16.7) | 2 (50) |
Lymph nodes | 3 (100) | 1 (33.3) | 2 (50) | 3 (50) | 2 (50) |
Bone | – | 1 (33.3) | – | – | – |
Others | – | 1 (33.3) | 1 (25) | 3 (50) | 2 (50) |
Treatment duration, median (range) (days) | 45 (25–132) | 27 (26–27) | 127 (48–270) | 87 (26–440 | 104 (59–180) |
Number of cycles of olaparib, median (range) | 2 (2–7) | 2 (2–2) | 6.5 (3–12) | 5 (2–19) | 4.5 (2–8) |
Number of cycles of lurbinectedin, median (range) | 3 (2–7) | 2 (2–2) | 6.5 (3–12) | 5 (2–19) | 4.5 (2–9) |
Total cumulative dose of olaparib, median (range) (mg) | 2000 (1700–6900) | 3000 (3000–3000) | 13,000 (5600–24,000) | 12,500 (5000–15,000) | 10,500 (6750–14,500) |
Total cumulative dose of lurbinectedin, median (range) (mg) | 5.1 (3.2–11.2) | 3.9 (3.4–4) | 17.5 (8.4–32.1) | 12.4 (5.7–41.5) | 12.3 (6.2–20) |
